Chris is a consultant on medicines safety, has a visiting academic appointment at the University of Cambridge and chairs the Nominations Subcommittee. He is Fellow of the Royal College of Pathologists, The Royal Society of Biology and the British Toxicology Society. Formerly, Chris was VP Translational Medicine and Safety at GlaxoSmithKline Pharmaceuticals. He has experience of working in biotech start-ups and was Reader in Pharmaceutical and Chemical Safety at St Bartholomew’s Hospital Medical College in London, where he led a research group working on mechanisms of hepatotoxicity. His interests are: the human relevance of experimental safety studies, the application of mechanisms of toxicity to risk assessment and epigenetic mechanisms of chemical carcinogenesis. Chris is a regular speaker at scientific meetings.
He has served on Scientific Advisory Committees for the UK/EU Government and for the World Health Organisation, the UK Dept Health Advisory Committee on Carcinogenicity, the Grant Review Panel for the MRC Integrated Toxicology Training Programme, the Strategic Governing Group on Translational Safety, for the European Union’s Innovative Medicines Initiative and he was chair of the British Pharmaceutical Industries Association Expert Network on Preclinical Safety.